CN102846696A - Traditional Chinese flavones extract for resisting ovarian function decline as well as preparation method and application thereof - Google Patents
Traditional Chinese flavones extract for resisting ovarian function decline as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN102846696A CN102846696A CN2012103903190A CN201210390319A CN102846696A CN 102846696 A CN102846696 A CN 102846696A CN 2012103903190 A CN2012103903190 A CN 2012103903190A CN 201210390319 A CN201210390319 A CN 201210390319A CN 102846696 A CN102846696 A CN 102846696A
- Authority
- CN
- China
- Prior art keywords
- flavone
- extract
- extracting solution
- preparation
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930003944 flavone Natural products 0.000 title claims abstract description 103
- 235000011949 flavones Nutrition 0.000 title claims abstract description 103
- 239000000284 extract Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 150000002213 flavones Chemical class 0.000 title claims abstract description 15
- 230000008717 functional decline Effects 0.000 title claims abstract description 12
- 230000002611 ovarian Effects 0.000 title abstract description 8
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 98
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 95
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 88
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 87
- 239000011347 resin Substances 0.000 claims abstract description 78
- 229920005989 resin Polymers 0.000 claims abstract description 78
- 239000003814 drug Substances 0.000 claims abstract description 50
- 238000000605 extraction Methods 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 27
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims abstract description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003208 petroleum Substances 0.000 claims abstract description 14
- 239000003480 eluent Substances 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 10
- 238000009835 boiling Methods 0.000 claims abstract description 9
- 238000004440 column chromatography Methods 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 37
- 238000000746 purification Methods 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- 210000000582 semen Anatomy 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 16
- 239000003463 adsorbent Substances 0.000 claims description 15
- 238000011068 loading method Methods 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 230000003068 static effect Effects 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 13
- 238000010828 elution Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 230000001476 alcoholic effect Effects 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 10
- 230000006837 decompression Effects 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000002390 rotary evaporation Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 230000010355 oscillation Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- -1 transfusion Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 238000005516 engineering process Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 5
- 238000001704 evaporation Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 3
- 244000020518 Carthamus tinctorius Species 0.000 abstract 3
- 240000007371 Cuscuta campestris Species 0.000 abstract 3
- 238000013329 compounding Methods 0.000 abstract 1
- 239000004519 grease Substances 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 30
- 239000000523 sample Substances 0.000 description 29
- 239000012488 sample solution Substances 0.000 description 17
- 238000001179 sorption measurement Methods 0.000 description 15
- 238000003795 desorption Methods 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 210000001672 ovary Anatomy 0.000 description 9
- 206010036601 premature menopause Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000002149 gonad Anatomy 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 5
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 5
- 235000005493 rutin Nutrition 0.000 description 5
- 229960004555 rutoside Drugs 0.000 description 5
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000000583 progesterone congener Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002657 hormone replacement therapy Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010036049 Polycystic ovaries Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001104043 Syringa Species 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229940063238 premarin Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a traditional Chinese flavones extract for resisting ovarian function decline as well as a preparation method and appliocation thereof and belongs to the field of traditional Chinese medicines. The preparation method of the traditional Chinese flavones extract specifically comprises the following steps: taking raw medicine materials, namely 100-400 parts of dodder and 7-32 parts of safflower; mixing and compounding 100-400 parts of dodder and 7-32 parts of safflower; uniformly stirring the dodder, the safflower, and large polarity extracting solution, the weight of which is 6-10 times of that of the raw medicine materials; and extracting the traditional Chinese flavones extract in the still state. The preparation method further comprises the following steps: collecting an extracting solution, decompressing and concentrating the extracting solution till the solution density of the extracting solution is 0.8-1.3g/ml, carrying out isopyknic extraction 3-6 times by petroleum ether with boiling range from 30DEG C to 60 DEG C in order to eliminate grease, eliminating a petroleum ether layer, carrying out sopyknic extraction on the water layer 3-6 times by ethyl acetate, evaporating the extract liquor in a rotating mode, and drying the extract liquor to obtain powder, namely the crudely extracted flavone components; and carrying out column chromatography with macroporous resin HPD450, collecting eluent, decompressing and recovering ethanol, decompressing and concentrating resultant, and drying the resultant to obtain the flavone component. The preparation method can be used for extracting and maintaining the flavone component from the effective component layer as more as possible through proper extracting and purifying methods and technologies so as to ensure the efficacy of the Chinese compound formula, so that the curative effect is enhanced, the dosage is reduced, the activity is definite, and the toxic and side effect is small.
Description
Technical field
The present invention relates to the field of Chinese medicines, relate to a kind of anti-ovarian function decline Chinese medicine flavone extract, Preparation method and use.
Background technology
Ovarian function decline can cause the serial diseases such as sterility and infertility, reproductive system, cardiovascular system, osteoporosis, ovary fail too early (Premature ovarian failure, POF, i.e. premature ovarian failure) cause patients ' life quality to descend.In addition, along with socioeconomic development, increasing working woman is selected to postpone bearing time, but women's best reproduction time window is subject to the serious restriction of ovarian function equally.Therefore inquiring into the index of ovarian function decline Aging mechanism, the decline of prediction ovarian function and preventing and treating the too early measure of decline of ovarian function is study hotspot and the difficult point in current healthy reproduction field.
Epidemiological study shows that the incidence rate of premature ovarian failure is 1%, yet how the women of this l% finally reaches the state of ovarian failure, and the state of POF starting stage how, still has at present a lot of the unknowns.Have research to find, with the age increase, follicle density descends gradually, and women's follicle density obviously reduces more than 35 years old, is that women's follicle density more than 1/4,40 years old of the follicle of person below 35 years old density sharply reduces, and some women follicle density is down to 0.Nikolaou estimates to have at least in population 10% women experiencing too early ovary decline, that is according to 1% incidence rate of POF, have at least 9% women to be in the early stage state that ovary fails, the expert is arranged to this state called after ovary aging (premature ovarian aging early, POA), and both etiology are compared research, the result has supported that POA is the viewpoint of a POF commitment performance.There is the effect of research prompting treatment High gonadotropic hormone amenorrhea relevant with the course of disease and FSH (FSH) level.
Hormone replacement therapy (Hormone replacement therapy, HRT) be the important method of the present old and feeble related symptoms of modern medicine treatment ovary and disease, but existing research shows that obviously it has multiple side effect and carcinogenecity at a specified future date, is subject to significant restrictions its clinical practice.
Summary of the invention
The present invention is directed to the prior art deficiency, follow Traditional Chinese medical theory according to China, adopt the Chinese medicinal formulae treatment, reach the purpose that delays the ovary aging by " the kidney invigorating tonifying YIN, soothing the liver nourishing blood ".The invention provides anti-ovarian function that a kind of Semen Cuscutae Flos Carthami prescription forms effective Chinese medicine compound that fails, from the effective site aspect, by suitable method for extraction and purification and technology, extract as much as possible and keep wherein flavone component, to guarantee the drug effect of Chinese medicine compound, improve curative effect, reduce dose, active clear and definite, toxic and side effects is little.
The present invention seeks to realize by following technical scheme:
A kind of Chinese medicine flavone extract of anti-ovarian function decline is prepared from by the following method:
1) gets crude drug by following weight portion: Semen Cuscutae 100-400 part, Flos Carthami 7-32 part, mix according to quantity and doubly measure mixture after large polarity extracting solution stirs with 6-10, under static state extract, can adopt sonic oscillation method, heating and refluxing extraction method or countercurrent extraction method, make be dissolved in the large polarity extracting solution of active component of the raw material in the mixture more.Described large polarity extracting solution preferred water, methanol, ethanol, or their any mixed liquor; Particularly preferably be concentration 60-80%(percent by volume), pH value is the alcoholic solution of 5.6-6.3;
2) collect extracting solution, concentrating under reduced pressure is 0.8-1.3g/ml to density, with 3-6 defat of 30-60 ℃ of petroleum ether equal-volume extraction of boiling range, discard petroleum ether layer, get aqueous layer extracted and extract 3-6 time the rotary evaporation extract with the ethyl acetate equal-volume, obtain powder after the drying, for slightly carrying the flavone position.
3) adopt the HPD450 macroporous adsorbent resin, preferably slightly put forward the sample solution concentration loading of flavone/ml with 0.2g, use respectively 8 times of (comparing with the wet resin amount) distilled water flush away impurity, then use 70% ethanol elution purification total flavones, collect eluent, decompression recycling ethanol, concentrating under reduced pressure, the dry total flavone part that gets.
Above-mentioned Chinese medicine flavone extract can be made preparation for administration separately or with one or more pharmaceutically acceptable carrier combinations, such as injection, transfusion, drop pill, tablet, capsule, granule, oral liquid etc.
The various dosage forms of Chinese medicine flavone extract of the present invention can be prepared according to the method for knowing in the pharmaceutical field.Can contain for example active component of 0.05% ~ 90% weight with carrier combinations in these pharmaceutical formulations, the active component of weight between more common about 15% ~ 60%.
The present invention also provide a kind of Chinese medicine flavone extract for preparing anti-ovarian function decline of the present invention method, comprise the steps:
1) gets crude drug by following weight portion: Semen Cuscutae 100-400 part, Flos Carthami 7-32 part, mix according to quantity and doubly measure mixture after large polarity extracting solution stirs with 6-10, under static state use sonic oscillation method, heating and refluxing extraction method or countercurrent extraction method, make be dissolved in the large polarity extracting solution of active component of the raw material in the mixture more.Described large polarity extracting solution preferred water, methanol, ethanol, or their any mixed liquor; Particularly preferably be concentration 60-80%, pH value is the alcoholic solution of 5.6-6.3;
2) collect extracting solution, concentrating under reduced pressure is 0.8-1.3g/ml to density, with 3-6 defat of 30-60 ℃ of petroleum ether equal-volume extraction of boiling range, discard petroleum ether layer, get aqueous layer extracted and extract 3-6 time the rotary evaporation extract with the ethyl acetate equal-volume, obtain powder after the drying, for slightly carrying the flavone position.
3) adopt the HPD450 macroporous adsorbent resin, slightly put forward the sample solution concentration loading of flavone/ml with 0.2g, use respectively 8 times of (comparing with the wet resin amount) distilled water flush away impurity, then use 70% ethanol elution purification total flavones, collect eluent, decompression recycling ethanol, concentrating under reduced pressure, the dry total flavone part that gets.
The present invention also provides the application of a kind of above-mentioned Chinese medicine flavone extract in the anti-ovarian function decline of preparation medicine.
The Chinese medicine compound that Chinese medicine flavone extract of the present invention adopts is comprised of the Semen Cuscutae Flos Carthami, wherein, Semen Cuscutae is warm in nature, sweet in the mouth, energy nourishing the liver and kidney, controlling nocturnal emission with astringent drugs reducing urination, antiabortive, make eye bright, antidiarrheal is suffered from a deficiency of the kidney and is rushed down for impotence and seminal emission, dripping urination, enuresis frequent micturition, soreness of the waist and knees, blurred vision tinnitus, vaginal bleeding due to deficiency of the kidney during pregnancy, frequent fetal movement, spleen; Externally treating leucoderma.Flos Carthami is warm in nature, acrid in the mouth, and the latus rectum of invigorating blood circulation, eliminating stasis to stop pain are used for amenorrhea, dysmenorrhea, lochia, lump in the abdomen mass in the abdomen, traumatic injury, applicable various varicosis, peripheral neuritis, blood circulation is bad, lower limb numbness or the congestion such as livid purple.Semen Cuscutae is the medicine of YANG invigorating, and the kidney invigorating and essence nourishing is arranged, nourishing the liver to improve visual acuity, the effect of antidiarrheal, Flos Carthami tool promoting blood circulation to remove obstruction in the collateral, the merit of stasis-dispelling and pain-killing can reach the kidney invigorating and essence nourishing, nourishing YIN and benefiting blood with the Semen Cuscutae compatibility, Yin Yang balancing, the effect of QI and blood regulating is applicable to the card of the hepatic and renal YIN deficiency, is the medicine of the tonifying YIN of enriching blood.Semen Cuscutae contains flavonoid, resin glycoside, saccharide.Flos Carthami contains a large amount of flavone compounds, and other contains volatile oil, plant sterol, polysaccharide, aminoacid, fatty acid, fatty wet goods.Therefore for the anti-ovarian function that has Semen Cuscutae Flos Carthami prescription to form effective Chinese medicine compound that fails, from the effective site aspect, so by suitable method for extraction and purification and technology, extract as much as possible and keep wherein flavone component, to guarantee the drug effect of Chinese medicine compound, that Chinese medicine (compound recipe) improves curative effect, less dose, a kind of feasible method of increase technology content.
The present invention had both kept the comprehensive function of each medicinal ingredient in the compound recipe, was conducive to bring into play the pleiotropy of Chinese medicine, had removed again suck tissue and partial invalidity composition, had prolonged the storage life, had improved purity, had reduced dose, and the repeatability of quality control improves.
Above-mentioned Chinese medicine flavone extract confirms the anti-ovarian function decline of its tool function through pharmacological evaluation, the preferred polycystic ovarian syndrome of described ovary degradation symptoms, functional menoxenia, premature ovarian failure or menopausal syndrome.
The present invention overcomes the characteristics that existing capsule taking dose is large, store inconvenience, time weak point, by using suitable solvent extraction to separate to full side's raw medicinal material and filtering out drug effect higher part position, keep the medical material effective ingredient, remove suck tissue and partial invalidity composition, active obviously raising reduces dose, strengthens drug compliance, the repeatability of quality control improves, convenient storage and transportation.Method technique of the present invention is simple and safe, and the resulting composition drug effect is better than former side's medical material, and production cost is low, is suitable for suitability for industrialized production, and the compositions of preparing is that active component can be made into various pharmaceutical dosage forms, such as soft capsule, tablet, drop pill, controlled release agent etc.
Description of drawings
Fig. 1 is the apoptotic index figure after the effect of flow cytometer detection of drugs.
The specific embodiment
Below with reference to specific embodiment the present invention is further elaborated, these examples only are used for illustration purpose, and are not used in the restriction scope of the invention.Laboratory animal of the present invention is available from Test Animal Centre, Academy of Military Medical Sciences, P.L.A (production licence number: SCXK (army) 2007-004).
The extraction purification of embodiment 1 Chinese medicine flavone extract of the present invention
Get double centner Semen Cuscutae and 7 kilograms of Flos Carthamis, add 1070 kilograms of pH value and be 5.6 60% soak with ethanol after 1 hour, refluxed 3 hours, 8 layers of filtered through gauze, medicinal residues are 5.6 60% alcohol reflux 2 hours with 428 kilograms of pH value; Concentrating under reduced pressure is 1.1g/ml to density, and with 5 defats of 30-60 ℃ of petroleum ether equal-volume extraction of boiling range, with ethyl acetate equal-volume extraction 3 times, the rotary evaporation extract obtains powder after the drying, for slightly carrying the flavone position.
Adopt the HPD450 macroporous adsorbent resin, with the sample solution concentration loading of 0.2g extract/ml, use respectively 8 times of (comparing with the wet resin amount) distilled water flush away impurity, then use 70% ethanol elution purification total flavones, collect eluent, decompression recycling ethanol, concentrating under reduced pressure, the dry total flavone part that gets.
The extraction purification of embodiment 2 Chinese medicine flavone extracts of the present invention
Get 250 kilograms of Semen Cuscutae and 20 kilograms of Flos Carthamis, pulverize the powder that obtains them through pulverizer respectively, the order numerical control is built in 80 orders.Be that 6 75% alcoholic solution mixes with above-mentioned powdery Semen Cuscutae Flos Carthami and 2160 kilograms of pH value, and in agitator, stir, then slowly flow into container through pipeline, tube wall at this pipeline is provided with supersonic generator, he carries out the sonic oscillation break process to the mixture of sluggish flow in the pipeline, processing time is 30 minutes, and the active component in the germinal cell fully is dissolved in the alcoholic solution.Mixture solution after the supersound process is filtered, remove residue, concentrating under reduced pressure is 1.0g/ml to density, with 3 defats of boiling range 30-60 ℃ of petroleum ether equal-volume extraction, with ethyl acetate equal-volume extraction 4 times, rotary evaporation extract, obtain powder after the drying, for slightly carrying the flavone position.
Adopt the HPD450 macroporous adsorbent resin, with the sample solution concentration loading of 0.2g extract/ml, use respectively 8 times of (comparing with the wet resin amount) distilled water flush away impurity, then use 70% ethanol elution purification total flavones, collect eluent, decompression recycling ethanol, concentrating under reduced pressure, the dry total flavone part that gets.
The extraction purification of embodiment 3 Chinese medicine flavone extracts of the present invention
Get 250 kilograms of Semen Cuscutae and 20 kilograms of Flos Carthamis, pulverize the powder that obtains them through pulverizer respectively, the order numerical control is built in 80 orders.Be 6 75% soak with ethanol after 1 hour with above-mentioned powdery Semen Cuscutae Flos Carthami and 2160 kilograms of pH value, refluxed 4 hours, 8 layers of filtered through gauze, medicinal residues are 6 75% alcohol reflux 3 hours with 1620 kilograms of pH value; Concentrating under reduced pressure is 0.8g/ml to density, and with 5 defats of 30-60 ℃ of petroleum ether equal-volume extraction of boiling range, with ethyl acetate equal-volume extraction 3 times, the rotary evaporation extract obtains powder after the drying, for slightly carrying the flavone position.
Adopt the HPD450 macroporous adsorbent resin, with the sample solution concentration loading of 0.2g extract/ml, use respectively 8 times of (comparing with the wet resin amount) distilled water flush away impurity, then use 70% ethanol elution purification total flavones, collect eluent, decompression recycling ethanol, concentrating under reduced pressure, the dry total flavone part that gets.
The extraction purification of embodiment 4 Chinese medicine flavone extracts of the present invention
Get 400 kilograms of Semen Cuscutae and 32 kilograms of Flos Carthamis, add 2592 kilograms of pH value and be 6.3 80% soak with ethanol after 1 hour, refluxed 3 hours, 8 layers of filtered through gauze, medicinal residues are 6.3 80% alcohol reflux 4 hours with 3456 kilograms of pH value; Concentrating under reduced pressure is 1.3g/ml to density, and with 5 defats of 30-60 ℃ of petroleum ether equal-volume extraction of boiling range, with ethyl acetate equal-volume extraction 3 times, the rotary evaporation extract obtains powder after the drying, for slightly carrying the flavone position.
Adopt the HPD450 macroporous adsorbent resin, with the sample solution concentration loading of 0.2g extract/ml, use respectively 8 times of (comparing with the wet resin amount) distilled water flush away impurity, then use 70% ethanol elution purification total flavones, collect eluent, decompression recycling ethanol, concentrating under reduced pressure, the dry total flavone part that gets.
Embodiment 5 sets up the Determination of Total Flavonoids method
1) reagent and instrument
Silon ethanol (analytical pure), methanol (analytical pure)
Rutin standard solution: take by weighing the 5.0mg rutin, add dissolve with methanol and be settled to 100mL, namely get 50 μ g/mL.
2) operational approach
Sample pretreating: take by weighing a certain amount of sample, add ethanol and be settled to 25mL, after shaking up, supersound extraction 20min places, and draws supernatant 1.0mL, in evaporating dish, adds the absorption of 1g Silon, flings to ethanol in water-bath, then changes chromatographic column over to.Wash with 20mL benzene first, benzene liquid discards, and then uses the methanol-eluted fractions flavone, is settled to 25mL.This liquid is measured absorption value in wavelength 286nm.Take rutin as standard substance, the bioassay standard curve is asked regression equation simultaneously, calculate general flavone content rutin standard curve in the sample: draw rutin standard solution 0,1.0,2.0,3.0,4.0,5.0mL in the 10mL color comparison tube, add methanol to scale, shake up, in wavelength 286nm colorimetric.Ask regression equation, calculate general flavone content in the sample.
Calculating and result represent (result of calculation keeps two position effective digitals)
In the formula: the content of total flavones in the X-sample, mg/100g; A-calculates to get flavone amount in the test solution, μ g by standard curve; The M-sample mass, g; V1-measures and uses volume of sample, mL; V2-sample standardize solution cumulative volume, mL.
Embodiment 6 slightly carries flavone purifying process conditional filtering
The simple flavone that adopts alcohol extracting method, hot water extraction or alkaline extraction all can't obtain high-load, the extracting solution of compound recipe or crude extract must could improve purity through after the separation and purification, purification process has recrystallization method, polyamide absorption column chromatography method and Flavonoids by Macroporous Adsorption Resin, also has in addition ultrafiltration, high performance liquid chromatography (HPLC) and blood capillary electrophoresis method etc.The industrial conventional Flavonoids by Macroporous Adsorption Resin that adopts.
1) material and reagent
HPD600, HPD480, HPD700, HPD750, HPD480 macroporous resin (Cangzhou, Hebei precious grace chemical industry company limited);
D101 macroporous resin (China Medicine University)
2) use macroporous adsorbent resin crude flavonoid powder is carried out purification
Study the Adsorption and desorption characteristics of macroporous adsorbent resin to flavone, therefrom filtered out the resin that is suitable for flavone of the present invention position purification, and used selected macroporous adsorbent resin that purification is carried out at the flavone position.
The pretreatment of resin
With wet method dress post behind the macroporous adsorbent resin usefulness soaked in absolute ethyl alcohol 24h; After resin installs,, add water to effluent and be not white in color till the muddiness, and be washed till without ethanol with same flow velocity with deionized water by resin bed with ethanol 2 BV/h; Then with 2 BV 0.5%HCl solution with 2.5 ml/min flow velocitys by resin bed, and soak behind the 2-4h water and be washed till the effluent pH value with same flow velocity and be neutral; Pass through resin bed with 2 BV 2%NaOH solution with the 2.5ml/min flow velocity at last, and after soaking 2-4 h, water is washed till effluent pH with same flow velocity and is neutral.
Different model resin technology index
The technical specification of several model macroporous adsorbent resins that we select sees table 1 for details.
Table 1 different model macroporous adsorbent resin technical specification
3 Staticadsorption experiment
Take by weighing respectively each each 1.0g of model resin (dry weight), put into the 250ml triangular flask, accurately add in the embodiment of the invention 1 and slightly carry flavone position extracting solution 100ml, place the water bath chader, be that 40 ℃, frequency of oscillation are under the 100Hz/min condition in temperature, vibration 12h is fully after the absorption, filter, get filtrate and survey its concentration.Be calculated as follows each resin adsorbance (Q, mg/g) at room temperature, determination data sees table 2 for details.
0r
In the formula: C
0Be the concentration (mg/ml) of adsorbing front flavone; C
rBe the concentration (mg/ml) of adsorbing rear flavone; V is sample solution volume (ml); W is resin quality (g).
Table 2 macroporous resin to the static adsorption Performance Ratio of flavone
As seen the static adsorbance size is arranged as: HPD700〉HPD750〉D101〉HPD480〉HPD450〉HPD600.
Static desorption experiment
Accurately take by weighing each the model resin after abundant saturated adsorption is slightly carried flavone, add respectively 30%, 50%, 70% and 90% each 30ml of alcoholic solution.Put into the water bath chader 12h that vibrates, filter, measure flavones content in the filtrate, calculate the desorption efficiency of each resin according to following formula, determination data sees table 18 for details.
Desorption efficiency (%)=C*V/Q*W*100
In the formula: C is the concentration (mg/ml) of flavone in the stripping liquid; V is the volume (ml) of eluent; Q is resin absorption amount (mg/g); W is the quality (g, weight in wet base) of used resin
Table 3 macroporous resin compares the static desorption performance of flavone
By above data analysis, visible alcoholic solution increases along with the increase of concentration of alcohol the desorption ability of flavone; And the alcoholic solution of same concentrations to the desorption ability that is adsorbed on the flavone on the resin is: HPD450〉HPD750〉HPD700〉D101〉HPD480〉HPD600.
Conclusion: by the macroporous resin of different model to the analysis of flavone static adsorption and desorption ability as seen, these six kinds of macroporous resins are more or less the same to the static adsorbance of flavone, but it is larger that desorption ability just differs, and only has HPD450 and HPD750 desorption ability stronger, can reach more than 80%.
The dynamic adsorption experiment
During the dress post, remain that resin is immersed in the distilled water, avoid Bubble formation on the impact of flavone separation and purification.After resin is added to predetermined column volume, repeatedly cross post with distilled water again, the resin in the post is fully compressed.The static placement of the resin column that installs is spent the night, and makes the resin in the post continue to compress until could use after fully settling out.During loading post top distilled water put to after the resin face flushes substantially, slowly add the sample solution of purification to be separated along tube wall from post top.Should note not communications centre pine top layer resin and make it floating and just rise.Under post, emit a little liquid, substantially flush with resin surface to the sample liquid level.Then add eluant, flow speed control is at 3-4ml/min, and the Fractional Collections eluent is measured flavone concentration wherein, draws elution curve.
Optimize the resin of HPD450 and two kinds of models of HPD750 by static adsorption and static desorption experiment, we just carry out the dynamic adsorption experiment relatively to these two kinds of model resins.As eluant, the flavone that is adsorbed on HPD450 and the HPD750 resin is carried out eluting with 90% alcoholic solution, every interval 30ml collects eluent, measures the concentration of flavone in the different eluant components, and concrete data see Table 4.Can find out, the elution curve peak shape of HPD450 resin is sharp-pointed, conditions of streaking is not obvious, show with 90% ethanol can make the flavone that is adsorbed on the HPD450 resin fast as eluant and the concentrated area elutes, further shown the desorption performance that the HPD450 resin is good to flavone.
Two kinds of macroporous resins of table 4 are to the dynamic desorption of flavone
The investigation of 6 sample solution concentration
Get 3 parts of each 10g of resin HPD450 that handle well, be respectively charged in the post of 2cm * 20cm, get a certain amount of flavone position of slightly carrying and so that not commensurability pure water is ultrasonic it is dissolved fully, be made into concentration and be respectively 0.2g extract/ml, 0.1g extract/ml, the sample liquid of 0.05g extract/ml, respectively complete loading, collect effluent, with the flavone sample liquid of not adsorbing between 20ml distilled water flushing resin slit, collect simultaneously, HPLC measures the content of its flavone, calculate saturated extent of adsorption, the results are shown in Table 5.
Table 5 sample solution concentration is investigated the result
| Sample solution concentration (the g extract/ml) | 0.2 | 0.1 | 0.05 |
| The sample solution peak area | 4990524.5 | 201393 16 | 17558314 |
| Flavone amount (g) in the sample solution | 0.52737939 | 0.42564905 | 0.37109899 |
| The effluent peak area | 4607545.5 | 5902886 | 8508222 |
| Flavone amount (g) in the effluent | 0.09738153 | 0.12475885 | 0.08991161 |
| Resin heavy (g) | 10.005 | 10.006 | 10.011 |
| Flavone adsorbance (mg/g resin) | 42.98 | 30.07 | 28.09 |
Sample solution concentration is larger, adsorption effect is better, but just be difficult to dissolving when in experimentation, finding preparation 0.2g extract/ml sample liquid, need long ultrasonic could the dissolving, the concentration that increases again sample solution just can not make it all dissolve, so we think that the sample solution concentration of 0.2g extract/ml is optium concentration (wherein the concentration of flavone is 15.33mg/ml).
. the investigation of absorption flow velocity
Get runic flavone aqueous solution (concentration of flavone is 15.33mg/ml) 34.4ml, be splined on respectively 6 10gHPD450 macroporous resins, respectively with 2,4,5,6, the flow velocity of 8ml/min carries out dynamic adsorption, take the content of flavone as index, measure the concentration after adsorbing, calculate saturated extent of adsorption, the results are shown in Table 6.
The investigation of table 6 absorption flow velocity
| Adsorption rate (ml/min) | Loading concentration (mg/ml) | Concentration after the loading (mg/ml) | Loading volume (ml) | Saturated extent of adsorption (mg/g) |
| 2 | 15.331 | 5.616 | 34.4 | 33.392 |
| 4 | 15.331 | 4.933 | 34.4 | 35.741 |
| 5 | 15.331 | 4.552 | 34.4 | 37.036 |
| 6 | 15.331 | 6.280 | 34.4 | 31.102 |
| 8 | 15.331 | 12.055 | 34.4 | 11.259 |
The result shows that when flow velocity was 2,4,5ml/min, the effect difference of absorption was very little, and is increased to 6ml/min when above, and adsorbance begins to descend with the increase of flow velocity, so this experiment is finally take 5ml/min as adsorbing flow velocity.
The investigation of washing amount
In the purification by macroporous resin process, owing in washing desaccharide process, the loss of flavone is arranged, so need to investigate it.Get the leakage that Exocarpium Citri Grandis aqueous solution (concentration of flavone is 15.33mg/ml) 15ml(assurance does not almost have loading to cause), be splined on the HPD450(10g of the 2cm * 20cm that handles well) on, fully use the deionized water eluting behind the absorption 12h, every 10ml is a unit, utilize the alpha-Naphthol concentrated sulphuric acid to carry out chromogenic reaction, measure simultaneously the content of flavone in the effluent.The results are shown in Table 7.
The investigation of table 7 washing amount
| Washing amount (ml) | Alpha-Naphthol concentrated sulphuric acid chromogenic reaction color | Reaction result | The concentration of flavone (mg/ml) in the effluent |
| 0~10 | The darkviolet colour circle | Reacting positive- | |
| 10~20 | The darkviolet colour circle | Reacting positive | 0.0013 |
| 20~30 | Than the darkviolet colour circle | Reacting positive | 0.0120 |
| 30~40 | The purple colour circle | Reacting positive | 0.0124 |
| 40~50 | The purple colour circle | Reacting positive | 0.0339 |
| 50~60 | The lilac colour circle | Reacting positive | 0.0414 |
| 60~70 | Without colour circle | Reaction negative | 0.0540 |
| 70~80 | Without colour circle | Reaction negative | 0.0940 |
| Sucrose solution | The darkviolet colour circle | Reacting positive | |
| Pure water | Without colour circle | Reaction negative |
The result shows, sugared reaction negative after the 70ml washing, flavone begins along with the increase of washing amount to run off, in order to guarantee sugared reaction negative and to guarantee in the less situation of flavone loss, some water-solubility impurities of removing more, the water elution amount is decided to be 80ml, i.e. 8 times of applied sample amount volumes, and the loss of flavone is 1.08% in this water-washing process.
So final definite: as to adopt the HPD450 macroporous adsorbent resin, sample solution concentration loading with 0.2g extract/ml, use respectively 8 times of (comparing with the wet resin amount) distilled water flush away impurity, then use 70% ethanol elution purification total flavones, collect eluent, decompression recycling ethanol, concentrating under reduced pressure, the dry total flavone part that gets.
The embodiment 7 different chemical parts that extract are on the impact of the gonad granulocyte activity that exsomatizes
Sample preparation: sample 1: by the total flavone part behind the purification that obtains in the embodiment of the invention 1; Sample 2: by the crude flavonoid powder part that obtains before the embodiment of the invention 1 center pillar chromatographic step.
Animal experiment method: get 22-27 age in days female rats, the cervical vertebra dislocation method is put to death behind the conventional 48h of raising, the aseptic bilateral ovaries of winning rat, granular cell is discharged the ovary fragmentation, contain with 2mL in the DMEM-F12 culture fluid of penicillin and streptomycin and dilute, and gently piping and druming, make it be dispersed into individual cells.Centrifugal filtration collecting granules cell.(1) mtt assay: with the finite concentration cell suspension inoculation in 24 orifice plates, every hole 80 μ l, every hole adds 120 μ l culture fluid again and adjusts cell density to 200 μ l/ hole, establishes 6 parallel holes for every group.Be placed on 5%CO
2Cultivate 24h in the incubator.Get CO
2Cultivated the granular cell suspension of 24h in the incubator, every hole successively adds modeling concentration Caddy (Cleary) and 1mgmL
-1Different samples, parallel setting Normal group (normal saline) and model group (Caddy (Cleary) and normal saline).In every hole, add MTT solution (5mgmL behind the cellar culture 20h
-1) 20 μ L continuation cultivation 4h, every hole adds three liquid of 80 μ L, and incubated overnight is selected the 570nm wavelength, measures each hole absorbance at enzyme-linked immunosorbent assay instrument, the results are shown in Table 8.(2) radioimmunology: with the finite concentration cell suspension inoculation in 24 orifice plates, every hole 80 μ l, every hole adds 120 μ l culture fluid again and adjusts cell density to 200 μ l/ hole, establishes 6 parallel holes for every group.Be placed on 5%CO
2Cultivate 24h in the incubator.Get CO
2Cultivated the granular cell suspension of 24h in the incubator, every hole successively adds modeling concentration Caddy (Cleary) and 1mgmL
-1Different samples, parallel setting Normal group (normal saline) and model group (Caddy (Cleary) and normal saline).Be placed on 5%CO
2Cultivate 24h in the incubator.Its cell conditioned medium liquid of centrifuging and taking is measured E with radioimmunological kit
2, P content, the results are shown in Table 8.(3) flow cytometry: after obtaining gonad granulocyte with method, the finite concentration cell culture in culture bottle, is successively added modeling concentration Caddy (Cleary) and 1mgmL
-1In different samples and the culture bottle, parallel setting Normal group (normal saline) and model group (Caddy (Cleary) and normal saline), digestion obtains cell suspension and carries out flow cytometer and detect (see figure 1) after 24 hours, analyzes the relation with apoptosis of administration and gonad granulocyte.
Mtt assay and radioimmunology as a result display model group and Normal group all have significant difference (p＜0.01) on cell-proliferation activity and estrogen and progestogen secretion capacity, visible modeling success.And under the same dose, sample 1 is suitable in the cell-proliferation activity effect with sample 2, but sample 1 estrogen and progestogen secretion capacity is better than sample 2, but all with model group significant difference (all p＜0.01) is arranged.
Table 8 is different extract chemical part on the impact of the gonad granulocyte activity that exsomatizes (
N=6)
| Group | Positive controls | | Sample 2 | Model group | Normal group |
| MTT trap (A) | 0.435±0.091 ** | 0.415±0.024 ** | 0.414±0.061 ** | 0.233±0.064 ΔΔ | 0.465±0.093 |
| Estrogen (pmol/L) | 83.89±5.33 ** | 81.29±1.86 ** | 76.36±2.51 ** | 36.19±1.98 ΔΔ | 101.85±6.38 |
| Progestogen (nmol/L) | 0.38±0.06 | 0.59±0.02 ** | 0.50±0.04 * | 0.36±0.03 ΔΔ | 0.69±0.07 |
*P＜0.05,
*P＜0.01vs model group.
ΔP＜0.05,
△ △P＜0.01vs Normal group
The flow cytometry result shows: in the accompanying drawing 1, UL represents dead cell, and UR represents the apoptosis in late period, and LL represents living cells, and LR represents early apoptosis, and UR+LR is the apoptosis total value.Figure 1A (Normal group) apoptosis value is 7.30, Figure 1B (model group) apoptosis value is 56.42, Fig. 1 C(positive controls) the apoptosis value is 27.02,1 group in Fig. 1 D(sample) the apoptosis value is 26.30,2 groups in Fig. 1 E(sample) the apoptosis value is 33.64, suitable to the anti-apoptotic effect of gonad granulocyte with positive drug (estradiol valerate) according to the visible sample of numerical value 1, be better than sample 2.
The anti-apoptotic effect of comprehensive gonad granulocyte cultivation effect, estrogen and progestogen secretion level and gonad granulocyte, every action activity that visible sample 1 is the flavone position behind the purification is all good, and purifying process is necessary.
Embodiment 8 Chinese medicine flavone extracts of the present invention are on the impact of Model of Polycystic Ovarian Syndrome rat
24d age teenage SD female rats, body weight 30-40g, 0.5mg18-methylnorethindron day 1 subcutaneous injection, at 27d during age, add with HCG 1.5IU day 2 subcutaneous injections, inject altogether 21d.After the modeling success, be divided at random the flavone position behind model group, the sample 1-4(purification, preparation is respectively with embodiment of the invention 1-4) group and positive drug group (metformin 0.018g/d), every group each 10, other gets 10 of 45d SD in age female rats and is Normal group, and every day, gavage was 1 time, Normal group and model group give the isometric(al) normal saline, behind the successive administration 15 days, get blood examination after the last administration and survey FSH, LH, T concentration in the serum, the results are shown in Table 9.Display model group and Normal group all have significant difference (p＜0.01) as a result, gavage positive drug, the present invention's (high low dosage) after 15 days FSH, LH, T level the difference of different significances is all arranged from model group.
The comparison of FSH, LH, T concentration in of the present invention group of table 9 and the matched group serum (
N=10)
*P＜0.05,
*P＜0.01vs model group.
ΔP＜0.05,
△ △P＜0.01vs Normal group
Embodiment 9 Chinese medicine flavone extracts of the present invention are on the impact of premature ovarian failure sex hormone level in rats
Adopt 9d SD in age female rats, continuously 14 days cyclophosphamide 8mg/(kgd of lumbar injection) modeling.After the modeling success, be divided at random the flavone position behind model group, the sample 1-4(purification, preparation is respectively with embodiment of the invention 1-4) group and positive drug group (premarin 0.075mg/kg), every group each 10, other gets 10 of 23d SD in age female rats and is Normal group, and every day, gavage was 1 time, and Normal group and model group give the isometric(al) normal saline, behind the successive administration 35 days, get blood examination after the last administration and survey FSH, E in the serum
2Concentration the results are shown in Table 10.Display model group and Normal group all have significant difference (p＜0.01) as a result, gavage positive drug, the present invention's (high low dosage) FSH, E after 35 days
2Level all has the difference of different significances from model group.
FSH, E in of the present invention group of table 10 and the matched group serum
2The comparison of concentration (
N=10)
*P＜0.05,
*P＜0.01vs model group.
ΔP＜0.05,
△ △P＜0.01vs Normal group.
Claims (10)
1. the Chinese medicine flavone extract of an anti-ovarian function decline is characterized in that being prepared from by the following method:
1) gets crude drug by following weight portion: Semen Cuscutae 100-400 part, Flos Carthami 7-32 part, mix according to quantity and with the 6-10 mixture after the large polarity extracting solution of crude drug weight stirs doubly, under static state use sonic oscillation method, heating and refluxing extraction method or countercurrent extraction method to extract, described large polarity extracting solution is water, the mixture of one or more in methanol or the ethanol;
2) collect extracting solution, concentrating under reduced pressure is that solution density is 0.8-1.3g/ml to density, with 3-6 defat of boiling range 30-60 ℃ of petroleum ether equal-volume extraction, discard petroleum ether layer, getting aqueous layer extracted extracts 3-6 time with the ethyl acetate equal-volume, the rotary evaporation extract obtains powder after the drying, for slightly carrying the flavone position;
3) adopt the HPD450 macroporous adsorbent resin to carry out column chromatography, collect eluent, decompression recycling ethanol, concentrating under reduced pressure, the dry total flavone part that gets.
2. Chinese medicine flavone extract as claimed in claim 1 is characterized in that described preparation method step 1) adopted heating and refluxing extraction 2-4 hour, filters, and gets filtrate, medicinal residues is doubly measured in the large polarity extracting solution backflow of medical material weight 2-4 hour with 4-8 again.
3. Chinese medicine flavone extract as claimed in claim 1 is characterized in that the described large polarity extracting solution of described preparation method step 1) is concentration 60-80%, and pH value is the alcoholic solution of 5.6-6.3.
4. Chinese medicine flavone extract as claimed in claim 1, it is characterized in that the described column chromatography condition of described preparation method step 3) is for slightly putting forward the concentration loading of flavone/ml with 0.2g, with 8 times of (comparing with the wet resin amount) volume distilled water flush away impurity, with 70% ethanol elution purification total flavones.
5. Chinese medicine flavone extract as claimed in claim 1 is characterized in that adding acceptable corresponding adjuvant on the pharmaceutics, and described medicament is injection, transfusion, drop pill, tablet, capsule, granule, oral liquid.
6. the preparation method of the described Chinese medicine flavone extract of claim 1 is characterized in that comprising the steps:
1) gets crude drug by following weight portion: Semen Cuscutae 100-400 part, Flos Carthami 7-32 part, mix according to quantity and doubly measure mixture after large polarity extracting solution stirs with 6-10, under static state use sonic oscillation method, heating and refluxing extraction method or countercurrent extraction method to extract, described large polarity extracting solution is water, the mixture of one or more in methanol or the ethanol;
2) collect extracting solution, concentrating under reduced pressure is 0.8-1.3g/ml to density, with 3-6 defat of 30-60 ℃ of petroleum ether equal-volume extraction of boiling range, discard petroleum ether layer, get aqueous layer extracted and extract 3-6 time the rotary evaporation extract with the ethyl acetate equal-volume, obtain powder after the drying, for slightly carrying the flavone position;
3) adopt the HPD450 macroporous adsorbent resin to carry out column chromatography, collect eluent, decompression recycling ethanol, concentrating under reduced pressure, the dry total flavone part that gets.
7. preparation method as claimed in claim 6 is characterized in that described step 1) adopted heating and refluxing extraction 2-4 hour, filters, and gets filtrate, medicinal residues is doubly measured in the large polarity extracting solution backflow of medical material weight 2-4 hour with 4-8 again.
8. such as claim 6 or 7 described preparation methoies, it is characterized in that the described large polarity extracting solution of described step 1) is concentration 60-80%, pH value is the alcoholic solution of 5.6-6.3.
9. preparation method as claimed in claim 6, it is characterized in that the described column chromatography condition of described step 3) is for slightly putting forward the concentration loading of flavone/ml with 0.2g, with 8 times of (comparing with the wet resin amount) volume distilled water flush away impurity, with 70% ethanol elution purification total flavones.
10. such as the application of the described Chinese medicine flavone extract of claim 1-5 in the anti-ovarian function decline of preparation medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210390319 CN102846696B (en) | 2012-10-15 | 2012-10-15 | Traditional Chinese flavones extract for resisting ovarian function decline as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210390319 CN102846696B (en) | 2012-10-15 | 2012-10-15 | Traditional Chinese flavones extract for resisting ovarian function decline as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102846696A true CN102846696A (en) | 2013-01-02 |
| CN102846696B CN102846696B (en) | 2013-09-11 |
Family
ID=47393941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210390319 Expired - Fee Related CN102846696B (en) | 2012-10-15 | 2012-10-15 | Traditional Chinese flavones extract for resisting ovarian function decline as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102846696B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114210096A (en) * | 2021-12-22 | 2022-03-22 | 广东石油化工学院 | Method for extracting and automatically separating volatile oil, flavonoid and polysaccharide from citrus grandis by column chromatography |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1519016A (en) * | 2003-09-01 | 2004-08-11 | 江苏省中国科学院植物研究所 | Prepared Chinese medicine for improving function of female ovary as well as preparation method and application in pharmacy |
| CN101084967A (en) * | 2007-07-05 | 2007-12-12 | 湖北中医学院 | Extracting and purifying technology for safflower flavonoids |
| CN101703554A (en) * | 2009-11-13 | 2010-05-12 | 段洪东 | Preparation and use of semen cuscutae flavonoids |
-
2012
- 2012-10-15 CN CN 201210390319 patent/CN102846696B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1519016A (en) * | 2003-09-01 | 2004-08-11 | 江苏省中国科学院植物研究所 | Prepared Chinese medicine for improving function of female ovary as well as preparation method and application in pharmacy |
| CN101084967A (en) * | 2007-07-05 | 2007-12-12 | 湖北中医学院 | Extracting and purifying technology for safflower flavonoids |
| CN101703554A (en) * | 2009-11-13 | 2010-05-12 | 段洪东 | Preparation and use of semen cuscutae flavonoids |
Non-Patent Citations (3)
| Title |
|---|
| 孙明等: "保健食品中植物雌激素类原料的安全性及其管理", 《毒理学杂志》, vol. 24, no. 4, 31 August 2010 (2010-08-31), pages 317 - 320 * |
| 李健英: "菟丝子中总黄酮提取工艺研究", 《哈尔滨商业大学学报（自然科学版）》, vol. 27, no. 1, 28 February 2011 (2011-02-28) * |
| 李娜等: "大孔吸附树脂分离纯化红花总黄酮的研究", 《食品工业科技》, no. 4, 31 December 2011 (2011-12-31), pages 276 - 279 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114210096A (en) * | 2021-12-22 | 2022-03-22 | 广东石油化工学院 | Method for extracting and automatically separating volatile oil, flavonoid and polysaccharide from citrus grandis by column chromatography |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102846696B (en) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102302525B (en) | Gingko leaf composition and preparation method thereof | |
| CN102198062A (en) | Red sage root mask and preparation method thereof | |
| CN106420849B (en) | A kind of Shu Xuening injection and preparation method thereof by compositions extracted from gingko biloba leaves preparation | |
| CN102875690A (en) | Anti-ovarian function recession Chinese medicinal polysaccharide extract, preparation method and application | |
| CN104804060B (en) | Preparing method of sodium aescinate, external use preparation comprising same and application thereof | |
| CN104725450B (en) | A kind of method that high-purity oleuropein is extracted from jasmine | |
| CN1197567C (en) | Application of kaempferol and its derivative in preparing medicine for cardiac and cerebral vascular diseases | |
| CN107823237A (en) | A kind of extracting method of burdock root total flavone | |
| CN101386613A (en) | Technique for extracting isoflavones materials from red clover | |
| CN109266688A (en) | A kind of preparation method and applications of Codonopsis pilosula polysaccharide | |
| CN101773553B (en) | Semiaquilegia root extract, preparation method and application thereof | |
| CN102228565A (en) | Preparation method and application of Vitex agnuscastus extract | |
| CN102846696B (en) | Traditional Chinese flavones extract for resisting ovarian function decline as well as preparation method and application thereof | |
| CN100496527C (en) | Preparation method and application of injection containing Erigeron breviscapus | |
| CN104434785A (en) | Crocetin salt injection and preparation process thereof | |
| CN107759657A (en) | The preparation method and application of peroxy-ergosterol compound | |
| CN101396460B (en) | Preparation method of anti-hemorrhoid extract containing rutin and naringin | |
| CN101439083A (en) | Chinese medicine soft capsules for clearing wind heat and clearing nasal passage, as well as preparation method and quality control method | |
| CN1903265B (en) | Traditional Chinese medicine composition for treating nycturia and its preparing method | |
| CN113512017B (en) | Compound in radish leaf groundsel and preparation method and application thereof | |
| CN101396422B (en) | Red clover extract and preparation method thereof | |
| CN100584345C (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, extraction method and application | |
| CN101011495A (en) | Kidney tonifying pill preparation made of fish air bladder and its preparation | |
| CN103405664B (en) | Daochi powder formula granule as well as preparation method, use and detection method thereof | |
| CN106420850B (en) | Compositions extracted from gingko biloba leaves and its preparing the application in Shu Xuening injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANJING WUYUE BIO-MEDICINE TECHNOLOGY DEVELOPMENT Free format text: FORMER OWNER: JIANGSU INSTITUTE OF BOTANY, CHINESE ACADEMY OF SCIENCES Effective date: 20150722 Free format text: FORMER OWNER: NANJING MEIFU NATURAL PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20150722 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150722 Address after: Zhe Lishui Economic Development Zone Zhetang town Nanjing city Jiangsu province 211200 Ning Road No. 368 Patentee after: Nanjing five sacred biological medicine science and Technology Development Co Ltd Address before: 210014 Zhongshan botanical garden, Zhongshan, Nanjing, Jiangsu Patentee before: Institute of Botany, Jiangsu Chinese Academy of Sciences Patentee before: Nanjing Meifu Natural Medicine Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130911 Termination date: 20191015 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |